Top

Published in:

01-10-2012 | Short Communication

HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

Authors: Scott R. Evans, Anthony J. Lee, Ronald J. Ellis, Huichao Chen, Kunling Wu, Ronald J. Bosch, David B. Clifford

Published in: Journal of NeuroVirology | Issue 5/2012

Abstract

The purpose of this study is to evaluate risk factors for progression from asymptomatic peripheral neuropathy (APN) to symptomatic peripheral neuropathy (SPN). Antiretroviral therapy (ART)-naïve patients initiating combination ART were followed longitudinally and screened for signs/symptoms of PN. Having APN was associated with higher odds of future SPN (odds ratio (OR) = 1.58, 95 % confidence interval (CI) = (1.08, 2.29), p = 0.027). Neurotoxic ART use was associated with increased odds of progression to SPN (OR = 2.16, 95 % CI = (1.21, 3.85), p = 0.009) while use of glucose-lowering drugs (non-insulin) was protective (OR = 0.12, 95 % CI = (0.02, 0.83), p = 0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN.

Cornblath DR, McArthur JC (1988) Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 38:794–796PubMedCrossRef

Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson D, Yiannoutsos CT, Yang Y, Robertson K, Neurological AIDS Research Consortium, AIDS Clinical Trials Group Study Teams, A5001 and A362 (2005) Clinical validation of the neuroscreen. J Neurovirol 11(6):503–511PubMedCrossRef

Ellis R, Rosario D, Clifford D, McArthur JC, Simpson D, Alexander T, Marra C, Gelman BB, Grant I (2009) Persisting high prevalence of HIV distal sensory peripheral neuropathy in the era of cART: Correlates in the CHARTER study [Paper #461]. CROI, Montreal

El-Mir MY, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S, Fontaine E, Almeida A, Leverve X (2008) Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34(10):77–87PubMedCrossRef

Eron JJ Jr, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, D'Aquila RT, Rogers MD, Tung R, Murphy RL (2000) The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). Am J Infect Dis 181(5):1622–1628CrossRef

Evans S, Li L (2005) A comparison of goodness of fit tests for the logistic GEE model. Statis Med 24:1245–1261CrossRef

Evans SR, Ellis RJ, Chen H, Yeh T, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB (2011) Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 25:919–928PubMedCrossRef

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH, Adult AIDS Clinical Trials Group 388 Study Team (2003) A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. Am J Infect Dis 188(5):625–634CrossRef

Forna F, Liechty C, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks J, Weidle P (2006) Early clinical toxicity to nonnucleoside reverse transcriptase inhibitor-based HAART in a home-based AIDS care program in rural Uganda [Abstract #142]. CROI, Denver

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group Study A5095 Team (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350(18):1850–1861PubMedCrossRef

Kim A, Ngan’ga L, Macharia D, Wangai M, Ilako F, Isavwa A, Marston B, Decock KM, Weidle P (2006) Adverse events in HIV-infected patients receiving ART in a treatment program in a Nairobi Slum, Kenya, 2003 to 2005 [Abstract #143]. CROI, Denver

Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O'Neil D, Schock B, Kuritzkes D, Lederman MM, AIDS Clinical Trials Group 5014 Team (2003) Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. Am J Infect Dis 188(10):1444–1454CrossRef

McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543–555PubMedCrossRef

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358(20):2095–2106PubMedCrossRef

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS, AIDS Clinical Trials Group 384 Team (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349(24):2293–2303PubMedCrossRef

Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, McClernon DR, Conant K, Cohen B, Epstein LG, Kieburtz K, NEAD Consortium (2005) Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 64:842–848PubMedCrossRef

Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, ACTG5117 Study Group (2006a) HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 66:1679–1687PubMedCrossRef

Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, ACTG A5117 Study Group (2006b) HIV Neuropathy Natural History Cohort Study: assessment measures and risk factors. Neurology 66:1679–1687PubMedCrossRef

Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, Benson CA (2008) AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 9:269–282PubMedCrossRef

Wulff EA, Wang AK, Simpson DM (2000) HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59:1251–1260PubMedCrossRef

Title: HIV peripheral neuropathy progression: protection with glucose-lowering drugs?
Authors: Scott R. Evans
Anthony J. Lee
Ronald J. Ellis
Huichao Chen
Kunling Wu
Ronald J. Bosch
David B. Clifford
Publication date: 01-10-2012
Publisher: Springer US
Published in: Journal of NeuroVirology / Issue 5/2012
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-012-0119-9

At a glance: The STEP trials

Springer Medicine

HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Disease-modifying drugs for multiple sclerosis and JC virus expression

Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells

Erratum to: Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria

Impact of opiate addiction on neuroinflammation in HIV

Antiretroviral neurotoxicity

Brain structural and functional recovery following initiation of combination antiretroviral therapy